de State Street Ligand Pharmaceuticals LGND Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | USD 261 M | Comprar |
834,685
+8,146
| +1% | +USD 2.41 M | 0.01% | 846 |
|
|
2026
Q2 | USD 261 M | Comprar |
826,539
+47,683
| +6% | +USD 11.2 M | 0.01% | 890 |
|
|
2026
Q1 | USD 155 M | Comprar |
778,856
+27,651
| +4% | +USD 5.47 M | 0.01% | 1100 |
|
|
2025
Q4 | USD 142 M | Comprar |
751,205
+1,845
| +0.2% | +USD 355 k | ﹤0.01% | 1153 |
|
|
2025
Q3 | USD 133 M | Vender |
749,360
-394
| -0.1% | -USD 58.6 k | ﹤0.01% | 1180 |
|
|
2025
Q2 | USD 85.2 M | Comprar |
749,754
+22,629
| +3% | +USD 2.42 M | ﹤0.01% | 1394 |
|
|
2025
Q1 | USD 76.4 M | Vender |
727,125
-16,507
| -2% | -USD 1.87 M | ﹤0.01% | 1408 |
|
|
2024
Q4 | USD 79.7 M | Comprar |
743,632
+36,218
| +5% | +USD 4.09 M | ﹤0.01% | 1481 |
|
|
2024
Q3 | USD 70.8 M | Comprar |
707,414
+18,642
| +3% | +USD 1.88 M | ﹤0.01% | 1521 |
|
|
2024
Q2 | USD 58 M | Comprar |
688,772
+17,488
| +3% | +USD 1.39 M | ﹤0.01% | 1587 |
|
|
2024
Q1 | USD 49.1 M | Comprar |
671,284
+3,000
| +0.4% | +USD 221 k | ﹤0.01% | 1739 |
|
|
2023
Q4 | USD 47.7 M | Comprar |
668,284
+45,029
| +7% | +USD 2.66 M | ﹤0.01% | 1727 |
|
|
2023
Q3 | USD 37.3 M | Comprar |
623,255
+10,643
| +2% | +USD 701 k | ﹤0.01% | 1794 |
|
|
2023
Q2 | USD 44.2 M | Vender |
612,612
-32,946
| -5% | -USD 2.47 M | ﹤0.01% | 1748 |
|
|
2023
Q1 | USD 47.5 M | Vender |
645,558
-4,356
| -0.7% | -USD 310 k | ﹤0.01% | 1682 |
|
|
2022
Q4 | USD 43.4 M | Vender |
649,914
-875,049
| -57% | -USD 56.9 M | ﹤0.01% | 1734 |
|
|
2022
Q3 | USD 81.9 M | Vender |
1,524,963
-212,556
| -12% | -USD 12.5 M | 0.01% | 1247 |
|
|
2022
Q2 | USD 96.7 M | Vender |
1,737,519
-12,625
| -0.7% | -USD 716 k | 0.01% | 1169 |
|
|
2022
Q1 | USD 123 M | Comprar |
1,750,144
+327,717
| +23% | +USD 23.8 M | 0.01% | 1150 |
|
|
2021
Q4 | USD 137 M | Vender |
1,422,427
-49,468
| -3% | -USD 4.57 M | 0.01% | 1060 |
|
|
2021
Q3 | USD 128 M | Comprar |
1,471,895
+94,200
| +7% | +USD 7.29 M | 0.01% | 1078 |
|
|
2021
Q2 | USD 113 M | Comprar |
1,377,695
+122,931
| +10% | +USD 10.2 M | 0.01% | 1206 |
|
|
2021
Q1 | USD 119 M | Vender |
1,254,764
-613,356
| -33% | -USD 58 M | 0.01% | 1103 |
|
|
2020
Q4 | USD 116 M | Comprar |
1,868,120
+310,602
| +20% | +USD 17.7 M | 0.01% | 1040 |
|
|
2020
Q3 | USD 92.6 M | Vender |
1,557,518
-61,813
| -4% | -USD 4.22 M | 0.01% | 1015 |
|
|
2020
Q2 | USD 113 M | Vender |
1,619,331
-388,840
| -19% | -USD 24.7 M | 0.01% | 877 |
|
|
2020
Q1 | USD 91.1 M | Vender |
2,008,171
-1,529
| -0.1% | -USD 86.7 k | 0.01% | 904 |
|
|
2019
Q4 | USD 131 M | Vender |
2,009,700
-27,216
| -1% | -USD 1.82 M | 0.01% | 881 |
|
|
2019
Q3 | USD 126 M | Comprar |
2,036,916
+150,244
| +8% | +USD 9.43 M | 0.01% | 868 |
|
|
2019
Q2 | USD 134 M | Vender |
1,886,672
-182,012
| -9% | -USD 13.4 M | 0.01% | 863 |
|
|
2019
Q1 | USD 162 M | Comprar |
2,068,684
+457,775
| +28% | +USD 34.7 M | 0.01% | 746 |
|
|
2018
Q4 | USD 136 M | Comprar |
1,610,909
+232,151
| +17% | +USD 24.7 M | 0.01% | 754 |
|
|
2018
Q3 | USD 236 M | Vender |
1,378,758
-81,137
| -6% | -USD 12.2 M | 0.02% | 648 |
|
|
2018
Q2 | USD 189 M | Vender |
1,459,895
-63,418
| -4% | -USD 7.08 M | 0.02% | 713 |
|
|
2018
Q1 | USD 157 M | Vender |
1,523,313
-27,633
| -2% | -USD 2.73 M | 0.01% | 780 |
|
|
2017
Q4 | USD 132 M | Comprar |
1,550,946
+184,522
| +14% | +USD 16 M | 0.01% | 861 |
|
|
2017
Q3 | USD 116 M | Comprar |
1,366,424
+65,378
| +5% | +USD 5.18 M | 0.01% | 902 |
|
|
2017
Q2 | USD 98.5 M | Vender |
1,301,046
-61,943
| -5% | -USD 4.33 M | 0.01% | 972 |
|
|
2017
Q1 | USD 90 M | Comprar |
1,362,989
+2,053
| +0.2% | +USD 135 k | 0.01% | 1012 |
|
|
2016
Q4 | USD 86.3 M | Vender |
1,360,936
-36,208
| -3% | -USD 2.28 M | 0.01% | 981 |
|
|
2016
Q3 | USD 88.9 M | Comprar |
1,397,144
+215,728
| +18% | +USD 15.8 M | 0.01% | 940 |
|
|
2016
Q2 | USD 87.9 M | Comprar |
1,181,416
+59,656
| +5% | +USD 4.43 M | 0.01% | 896 |
|
|
2016
Q1 | USD 74.9 M | Comprar |
1,121,760
+103,249
| +10% | +USD 6.28 M | 0.01% | 965 |
|
|
2015
Q4 | USD 68.9 M | Comprar |
1,018,511
+71,779
| +8% | +USD 4.43 M | 0.01% | 997 |
|
|
2015
Q3 | USD 50.6 M | Vender |
946,732
-22,645
| -2% | -USD 1.37 M | 0.01% | 1167 |
|
|
2015
Q2 | USD 61 M | Vender |
969,377
-68,303
| -7% | -USD 3.73 M | 0.01% | 1146 |
|
|
2015
Q1 | USD 49.9 M | Vender |
1,037,680
-34,831
| -3% | -USD 1.33 M | 0.01% | 1242 |
|
|
2014
Q4 | USD 35.6 M | Comprar |
1,072,511
+34,871
| +3% | +USD 1.13 M | ﹤0.01% | 1403 |
|
|
2014
Q3 | USD 30.4 M | Comprar |
1,037,640
+120,750
| +13% | +USD 4.01 M | ﹤0.01% | 1436 |
|
|
2014
Q2 | USD 35.6 M | Vender |
916,890
-28,032
| -3% | -USD 1.14 M | ﹤0.01% | 1406 |
|
|
2014
Q1 | USD 39.6 M | Vender |
944,922
-63,301
| -6% | -USD 2.64 M | ﹤0.01% | 1328 |
|
|
2013
Q4 | USD 33.1 M | Vender |
1,008,223
-213,265
| -17% | -USD 6.95 M | ﹤0.01% | 1432 |
|
|
2013
Q3 | USD 33 M | Comprar |
1,221,488
+403,762
| +49% | +USD 11.4 M | ﹤0.01% | 1396 |
|
|
2013
Q2 | USD 19.1 M | Comprar |
+817,726
| Nuevas | +USD 14.7 M | ﹤0.01% | 1658 |
|
Otros fondos que tienen LGND en su cartera
Posición de State Street en LGND: resumen de T3 2026
State Street aumentó su participación en Ligand Pharmaceuticals (LGND) en 0.99% durante T3 2026, al comprar aproximadamente USD 2.41 M y elevar la posición a 834,685 acciones con un valor de USD 261 M. La posición representa 0.01% de la cartera y ocupa el puesto #846.
State Street reportó por primera vez una posición en LGND en T2 2013 y la ha mantenido durante 54 trimestres desde entonces. La posición alcanzó su máximo de USD 261 M en T2 2026. Al cierre de T3 2026, 348 fondos que sigue Wall St. Rank mantienen una posición en LGND.
- Al cierre de T3 2026, State Street tenía 834,685 acciones de Ligand Pharmaceuticals con un valor de USD 261 M.
- State Street compró 8,146 acciones de Ligand Pharmaceuticals en T3 2026, por un monto estimado de USD 2.41 M.
- Ligand Pharmaceuticals representó 0.01% de la cartera de State Street en T3 2026 y fue su posición número 846.
- State Street reportó por primera vez una posición en Ligand Pharmaceuticals en T2 2013 y la ha mantenido durante 54 trimestres desde entonces.
- La posición de State Street en Ligand Pharmaceuticals alcanzó su máximo de USD 261 M en T2 2026.
- Al cierre de T3 2026, 348 fondos que sigue Wall St. Rank tenían Ligand Pharmaceuticals en cartera.
Según el Informe 13F de State Street correspondiente a T3 2026, presentado el 12 nov 2026.